8 August, 2016
Latest news on emerging technologies in healthcare; New report on Chordate System S100 for chronic non-allergic rhinitis by the National Institute for Health Research in the UK.
NIHR has issued a new report on our system.
NIHR evaluates the effectiveness and impact of new healthcare treatments. The NIHR Horizon Scanning Research & Intelligence Centre (NIHR HSRIC) was established as an independent research team at the University of Birmingham. The NIHR HSRIC aims to supply timely information to key policy-and decision-makers and research funders within the English National Health Service (NHS) about emerging health technologies that may have a significant impact on patients or the provision of health services in the near future.
Follow the link to download the report.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.